Abeona Therapeutics’ (ABEO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report issued on Wednesday morning, Marketbeat Ratings reports. The firm currently has a $15.00 price objective on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th. StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 14th.

Abeona Therapeutics Stock Performance

NASDAQ ABEO opened at $5.86 on Wednesday. The company has a market cap of $254.73 million, a P/E ratio of -2.18 and a beta of 1.43. The company has a fifty day simple moving average of $5.65 and a 200 day simple moving average of $5.80. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ABEO. Adage Capital Partners GP L.L.C. raised its holdings in shares of Abeona Therapeutics by 20.1% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock worth $21,736,000 after purchasing an additional 652,366 shares during the period. Western Standard LLC raised its stake in shares of Abeona Therapeutics by 22.8% in the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock valued at $11,610,000 after buying an additional 386,321 shares during the period. abrdn plc lifted its position in shares of Abeona Therapeutics by 158.8% during the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after buying an additional 200,647 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Abeona Therapeutics by 894.8% during the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock worth $732,000 after acquiring an additional 118,262 shares during the period. Finally, 683 Capital Management LLC increased its holdings in Abeona Therapeutics by 17.3% in the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock worth $4,411,000 after acquiring an additional 116,845 shares during the last quarter. 80.56% of the stock is owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.